Calgary, AB — September 4, 2025 — Leads & Copy — Syantra, Inc., a biotechnology company revolutionizing cancer detection, today announced a new therapeutic division focused on developing first-in-class therapies to reverse cancer-related immune cell corruption and restore anti-cancer immunity.
The company’s patent-pending Onco-ID™ platform leverages signals from the immune system to detect active cancer signatures, providing a unique focus on tumor-immune reprogramming.
CEO Rob Lozuk stated that the biological mechanisms used to detect early-stage cancers can be adapted to identify new drug targets and create new paths to treatment, with specific targets and approaches already advanced.
The technology may also improve therapeutic outcomes through patient selection and treatment monitoring.
Principal Scientist Olesya Kharenko, PhD, explained that tumors ‘educate’ the body’s immune cells, reducing their ability to combat disease. Syantra’s platform replicates a person’s biology in proprietary laboratory models to discover new targets that can reverse tumor education.
Syantra is continuing clinical testing of its multi-target whole blood mRNA test and has secured additional funding to support its clinical and commercial efforts. Several rounds of patent filings have been completed with additional applications forthcoming.
Media contact: Rob Lozuk (rob.lozuk@syantra.com)
Source: Syantra Inc.
